ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis

Journal of Lipid Research

Volumn 52, Issue 8, 2011, Pages 1461-1470

  Wang, Yaoyong ^a   Sawashita, Jinko ^a   Qian, Jinze ^a   Zhang, Beiru ^a   Fu, Xiaoying ^a   Tian, Geng ^a   Chen, Lei ^a   Mori, Masayuki ^a   Higuchi, Keiichi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Age; Amyloid heart disease; Apolipoproteins; Cholesterol; Distribution; Lipids

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HEART; HEART AMYLOIDOSIS; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PARTICLE SIZE; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC DISEASE; TRIACYLGLYCEROL BLOOD LEVEL;

AGING; AMYLOID; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; CHOLESTEROL, HDL; FEMALE; GENE DELETION; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; PARTICLE SIZE; RNA, MESSENGER; TRIGLYCERIDES;

EID: 79960690007     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M013235     Document Type: Article

References (43)

1. Kontush, A., and M. J. Chapman. 2006. Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol. Rev. 58: 342-374.
2. Chapman, M. J. 1980. Animal lipoproteins: chemistry, structure, and comparative aspects. J. Lipid Res. 21: 789-853. (Pubitemid 11230305)
3. Sorci-Thomas, M. G., S. Bhat, and M. J. Thomas. 2009. Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. Clin. Lipidol. 4: 113-124.
4. Duffy, D., and D. J. Rader. 2009. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6: 455-463.
5. Schaefer, E. J., R. D. Santos, and B. F. Asztalos. 2010. Marked HDL deficiency and premature coronary heart disease. Curr. Opin. Lipidol. 21: 289-297.
6. Al-Sarraf, A., K. Al-Ghofaili, D. R. Sullivan, K. M. Wasan, R. Hegele, and J. Frohlich. 2010. Complete ApoAI deficiency in an Iraqi Mandaean family: case studies and review of the literature. J. Clin. Lipidol. 4: 420-426.
7. Li, H., R. L. Reddick, and N. Maeda. 1993. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler. Thromb. 13: 1814-1821.
8. Kalopissis, A. D., and J. Chambaz. 2000. Transgenic animals with altered high-density lipoprotein composition and functions. Curr. Opin. Lipidol. 11: 149-153. (Pubitemid 30219109)
9. Lee, M., L. Calabresi, G. Chiesa, G. Franceschini, and P. T. Kovanen. 2002. Mast cell chymase degrades apoE and apoA-II in apoA-Iknockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 22: 1475-1481.
10. Duverger, N., G. Tremp, J. M. Caillaud, F. Emmanuel, G. Castro, J. C. Fruchart, A. Steinmetz, and P. Denefle. 1996. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 273: 966-968. (Pubitemid 26275175)
11. Blanco-Vaca, F., J. C. Escolà-Gil, J. M. Martín-Campos, and J. Julve. 2001. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res. 42: 1727-1739. (Pubitemid 33116704)
12. Deeb, S. S., K. Takata, R. L. Peng, G. Kajiyama, and J. J. Albers. 1990. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am. J. Hum. Genet. 46: 822-827.
13. Koike, T., S. Kitajima, Y. Yu, Y. Li, K. Nishijima, E. Liu, H. Sun, A. B. Waqar, N. Shibata, T. Inoue, et al. 2009. Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 29: 2047-2053.
14. Ge, F., J. Yao, X. Fu, Z. Guo, J. Yan, B. Zhang, H. Zhang, H. Tomozawa, J. Miyazaki, J. Sawashita, et al. 2007. Amyloidosis in transgenic mice expressing murine amyloidogenic apolipoprotein A-II (Apoa2c). Lab. Invest. 87: 633-643. (Pubitemid 46920103)
15. Weng, W., and J. L. Breslow. 1996. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. USA. 93: 14788-14794.
16. Castellani, L. W., A. M. Goto, and A. J. Lusis. 2001. Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes. 50: 643-651.
17. Thompson, P. A., J. F. Berbée, P. C. Rensen, and R. L. Kitchens. 2008. Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein. Innate Immun. 14: 365-374.
18. Escolà-Gil, J. C., A. Marzal-Casacuberta, J. Julve-Gil, B. Y. Ishida, J. Ordóñez-Llanos, L. Chan, F. González-Sastre, and F. Blanco-Vaca. 1998. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J. Lipid Res. 39: 457-462. (Pubitemid 28100682)
19. Warden, C. H., C. C. Hedrick, J. H. Qiao, L. W. Castellani, and A. J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261: 469-472.
20. Benson, M. D., J. J. Liepnieks, M. Yazaki, T. Yamashita, A. K. Hamidi, B. Guenther, and B. Kluve-Beckerman. 2001. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics. 72: 272-277. (Pubitemid 32281528)
21. Xing, Y., and K. Higuchi. 2002. Amyloid fibril proteins. Mech. Ageing Dev. 123: 1625-1636. (Pubitemid 35449226)
22. Higuchi, K., J. Wang, K. Kitagawa, T. Matsushita, K. Kogishi, H. Naiki, H. Kitado, and M. Hosokawa. 1996. Accelerated senile amyloidosis induced by amyloidogenic Apoa-II gene shortens the life span of mice but does not accelerate the rate of senescence. J. Gerontol. A Biol. Sci. Med. Sci. 51: B295-B302. (Pubitemid 26256318)
23. Kitagawa, K., J. Wang, T. Mastushita, K. Kogishi, M. Hosokawa, X. Fu, Z. Guo, M. Mori, and K. Higuchi. 2003. Polymorphisms of mouse apolipoprotein A-II: seven alleles found among 41 inbred strains of mice. Amyloid. 10: 207-214. (Pubitemid 38117504)
24. Xing, Y., A. Nakamura, T. Korenaga, Z. Guo, J. Yao, X. Fu, T. Matsushita, K. Kogishi, M. Hosokawa, F. Kametani, et al. 2002. Induction of protein conformational change in mouse senile amyloidosis. J. Biol. Chem. 277: 33164-33169. (Pubitemid 34984834)
25. Bekaert, E. D., P. Alaupovic, C. Knight-Gibson, R. A. Norum, M. J. Laux, and M. Ayrault-Jarrier. 1992. Isolation and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma. Biochim. Biophys. Acta. 1126: 105-113.
26. Lefterov, I., N. F. Fitz, A. A. Cronican, A. Fogg, P. Lefterov, R. Kodali, R. Wetzel, and R. Koldamova. 2010. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1 Delta E9 mice. J. Biol. Chem. 285: 36945-36957.
27. Williamson, R., D. Lee, J. Hagaman, and N. Maeda. 1992. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89: 7134-7138.
28. Okazaki, M., S. Usui, M. Ishigami, N. Sakai, T. Nakamura, Y. Matsuzawa, and S. Yamashita. 2005. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol. 25: 578-584. (Pubitemid 40315681)
29. Umezawa, M., K. Tatematsu, T. Korenaga, X. Fu, T. Matushita, H. Okuyama, M. Hosokawa, T. Takeda, and K. Higuchi. 2003. Dietary fat modulation of apoA-II metabolism and prevention of senile amyloidosis in the senescence- accelerated mouse. J. Lipid Res. 44: 762-769. (Pubitemid 37279678)
30. Higuchi, K., T. Yonezu, K. Kogishi, A. Matsumura, S. Takeshita, K. Higuchi, A. Kohno, M. Matsushita, M. Hosokawa, and T. Takeda. 1986. Purification and characterization of a senile amyloid-related antigenic substance (apoSASSAM) from mouse serum. apoSAS-SAM is an apoA-II apolipoprotein of mouse high density lipoproteins. J. Biol. Chem. 261: 12834-12840. (Pubitemid 17204248)
31. Higuchi, K., A. Matsumura, A. Honma, S. Takeshita, K. Hashimoto, M. Hosokawa, K. Yasuhira, and T. Takeda. 1983. Systemic senile amyloid in senescence-accelerated mice. A unique fibril protein demonstrated in tissues from various organs by the unlabeled immunoperoxidase method. Lab. Invest. 48: 231-240. (Pubitemid 13144384)
32. Korenaga, T., X. Fu, Y. Xing, T. Matsusita, K. Kuramoto, S. Syumiya, K. Hasegawa, H. Naiki, M. Ueno, T. Ishihara, et al. 2004. Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils. Am. J. Pathol. 164: 1597-1606. (Pubitemid 38529762)
33. Higuchi, K., H. Kitado, K. Kitagawa, K. Kogishi, H. Naiki, and T. Takeda. 1993. Development of congenic strains of mice carrying amyloidogenic apolipoprotein A-II (Apoa2c). Apoa2c reduces the plasma level and the size of high density lipoprotein. FEBS Lett. 317: 207-210. (Pubitemid 23045790)
34. Zhang, H., J. Sawashita, X. Fu, T. Korenaga, J. Yan, M. Mori, and K. Higuchi. 2006. Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods. FASEB J. 20: 1012-1014.
35. Fu, L., I. Matsuyama, T. Chiba, Y. Xing, T. Korenaga, Z. Guo, X. Fu, J. Nakayama, M. Mori, and K. Higuchi. 2001. Extrahepatic expression of apolipoprotein A-II in mouse tissues: possible contribution to mouse senile amyloidosis. J. Histochem. Cytochem. 49: 739-748.
36. Castellani, L. W., M. Navab, B. J. Van Lenten, C. C. Hedrick, S. Y. Hama, A. M. Goto, A. M. Fogelman, and A. J. Lusis. 1997. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J. Clin. Invest. 100: 464-474.
37. Ribas, V., J. L. Sánchez-Quesada, R. Antón, M. Camacho, J. Julve, J. C. Escolà-Gil, L. Vila, J. Ordóñez-Llanos, and F. Blanco-Vaca. 2004. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ. Res. 95: 789-797. (Pubitemid 39390581)
38. Rotllan, N., V. Ribas, L. Calpe-Berdiel, J. M. Martín-Campos, F. Blanco-Vaca, and J. C. Escolà-Gil. 2005. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 25: e128-e132.
39. Alaupovic, P., C. Knight-Gibson, C. S. Wang, D. Downs, E. Koren, H. B. Brewer, Jr., and R. E. Gregg. 1991. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J. Lipid Res. 32: 9-19.
40. Weers, P. M., A. B. Patel, L. C. Wan, E. Guigard, C. M. Kay, A. Hafiane, R. McPherson, Y. L. Marcel, and R. S. Kiss. 2011. Novel N-terminal mutation of human apolipoprotein A-I reduces selfassociation and impairs LCAT activation. J. Lipid Res. 52: 35-44.
41. Zhou, H., Z. Li, D. L. Silver, and X. C. Jiang. 2006. Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor. Biochim. Biophys. Acta. 1761: 1482-1488.
42. Hassan, W., H. Al-Sergani, W. Mourad, and R. Tabbaa. 2005. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex. Heart Inst. J. 32: 178-184. (Pubitemid 40800126)
43. Higuchi, K., A. Matsumura, A. Honma, K. Toda, S. Takeshita, M. Matsushita, T. Yonezu, M. Hosokawa, and T. Takeda. 1984. Age-related changes of serum apoprotein SASSAM, apoprotein A-I and low-density lipoprotein levels in senescence accelerated mouse (SAM). Mech. Ageing Dev. 26: 311-326. (Pubitemid 14033336)